MIMVaC-Africa is an ambitious programme that aims to test a portfolio of five malaria vaccine candidates to identify the most promising candidate that could be tested in large Phase 3 trials. In addition, the programme will help strengthen clinical trial infrastructure and vaccine development capabilities at African sites.
The multilateral collaboration of experts from ten Asian, European and African institutions; convergence of resources and energies; and the use of modern research techniques such as controlled malaria infections in humans, are assets that will enable our consortium to achieve its objectives on time.
Since the official launch of the program on 01 February 2020, I am very pleased to see activities gradually being deployed on the ground despite the Covid-19 pandemic constraints. This is an opportunity for me to express my gratitude to the partner institutions and to the European & Developing Countries Clinical Trials Partnership (EDCTP) of the European Union, which is funding our initiative to the tune of more than 11 million Euros.
I look forward to the development of malaria vaccine, the ultimate response to save thousands of young lives lost early due to malaria.
Dr Sodiomon B. SIRIMA